TIDMONC

RNS Number : 3806W

Oncimmune Holdings PLC

11 December 2023

11 DECEMBER 2023

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Director/PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, has been notified that on 8 December 2023, Mr Martin Gouldstone, PDMR and Chief Executive Officer, purchased 36,023 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") at a price of GBP0.2725 per share.

Following this transaction Mr Gouldstone has a total interest in the Company of 36,023 Ordinary Shares, representing approximately 0.05 per cent of the Company's issued share capital of 74,142,147. In addition, Mr Gouldstone holds options over 589,971 Ordinary Shares, representing approximately 0.8 per cent of the Company's issued share capital.

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                    Mr Martin Gouldstone 
      --------------------------------------  -------------------------------------- 
       Reason for the notification 
  2 
      ------------------------------------------------------------------------------ 
 a)    Position/status                         Chief Executive Officer 
      --------------------------------------  -------------------------------------- 
 b)    Initial notification                    Initial Notification 
        /Amendment 
      --------------------------------------  -------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------ 
 a)    Name                                    Oncimmune Holdings plc 
      --------------------------------------  -------------------------------------- 
 b)    LEI                                     213800HCYIWT6YPI1I02 
      --------------------------------------  -------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4     for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------ 
 a)    Description of the                      Ordinary Shares of GBP0.01 each 
        financial instrument, 
        type of instrument 
 
       Identification code                     ISIN: GB00BYQ94H38 
 
 b)    Nature of the transaction               Purchase of Ordinary Shares 
      --------------------------------------  -------------------------------------- 
 c)    Price(s) and volume(s) 
                                               -----------------  ---------------- 
                                                Price(s)           Volume(s) 
                                               -----------------  ---------------- 
    GBP0.2725                                                      36,023 
   -------------------------------------------------------------  ---------------- 
 
 d)    Aggregated information                  N/A - single transaction 
 
  - Aggregated volume 
 
  - Price 
 
 e)    Date of the transaction                 8 December 2023 
      --------------------------------------  -------------------------------------- 
 f)    Place of the transaction                London Stock Exchange, AIMX 
      --------------------------------------  --------------------------------------

For further information:

contact@oncimmune.co.uk

Singer Capital Markets (Nominated Adviser and Broker)

Phil Davies, Harry Gooden, James Fischer

+44 (0)20 7496 3000

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

About Oncimmune

Oncimmune is a global leader in immune biomarkers and immunodiagnostics, offering autoantibody biomarker profiling in immunooncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS(TM) technology platform, the Company provides insights and analytics to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEFLFFXLLFFBB

(END) Dow Jones Newswires

December 11, 2023 10:12 ET (15:12 GMT)

Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Oncimmune Charts.
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Oncimmune Charts.